Key result
Amodiaquine and desethylamodiaquine caused concentration-dependent decreases in pulse rate (1.9 beats/min per 100 nmol/L; 95% CI 1.5-2.4) and blood pressure, and prolonged the QT interval.
Why the study?
Amodiaquine can cause bradycardia, hypotension, and QT interval prolongation, but the relationship of these changes to drug concentrations is not well characterized.
What is the concentration-effect relationship of amodiaquine and desethylamodiaquine on heart rate, blood pressure, and electrocardiograph intervals in adults with uncomplicated malaria?
Observational (n=54)
What is the concentration-effect relationship of amodiaquine and desethylamodiaquine on heart rate, blood pressure, and electrocardiograph intervals in adults with uncomplicated malaria?
Amodiaquine and its active metabolite desethylamodiaquine exert concentration-dependent bradycardic, hypotensive, and QT-prolonging effects, highlighting the need for cardiac safety monitoring during treatment.
May support cardiac monitoring during amodiaquine malaria therapy; leaves open need for randomized confirmation of concentration-dependent effects.
AIMS: Amodiaquine is a 4-aminoquinoline used extensively for the treatment and prevention of malaria. Orally administered amodiaquine is largely converted to the active metabolite desethylamodiaquine. Amodiaquine can cause bradycardia, hypotension, and electrocardiograph QT interval prolongation, but the relationship of these changes to drug concentrations is not well characterized. METHODS: We conducted a secondary analysis of a pharmacokinetic study of the cardiac safety of amodiaquine (10 mg base/kg/day over 3 days) in 54 Kenyan adults (≥18 years) with uncomplicated malaria. Nonlinear mixed effects modelling was used to assess amodiaquine and desethylamodiaquine concentration-effect relationships for vital sign (pulse rate, blood pressure) and electrocardiograph interval (QT, QRS, PR) outcomes. We also measured the spontaneous beating heart rate after cumulative dosing of amodiaquine and desethylamodiaquine in isolated mouse atrial preparations. RESULTS: Amodiaquine and desethylamodiaquine caused concentration-dependent mean decreases in pulse rate (1.9 beats/min per 100 nmol/L; 95% confidence interval: 1.5-2.4), supine systolic blood pressure (1.7 mmHg per 100 nmol/L; 1.2-2.1), erect systolic blood pressure (1.5 mmHg per 100 nmol/L; 1.0-2.0) and erect diastolic blood pressure (1.4 mmHg per 100 nmol/L; 1.0-1.7). The mean QT interval prolongation was 1.4 ms per 100 nmol/L irrespective of correction factor after adjustment for residual heart rate dependency. There was no significant effect of drug concentration on postural change in blood pressure or PR and QRS intervals. In mouse atria, the spontaneous beating rate was significantly reduced by amodiaquine (n = 6) and desethylamodiaquine (n = 8) at 3 μmol/L (amodiaquine: 10 ± 2%; desethylamodiaquine: 12 ± 3%) and 10 μmol/L (amodiaquine: 50 ± 7%; desethylamodiaquine: 46 ± 6%) concentrations with no significant difference in potency between the 2 compounds. CONCLUSION: Amodiaquine and desethylamodiaquine have concentration-dependent effects on heart rate, blood pressure, and ventricular repolarization.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2022) conducted an observational in uncomplicated malaria (n=54). Amodiaquine and desethylamodiaquine concentrations was evaluated on pulse rate (Mean decrease 1.9 beats/min per 100 nmol/L, 95% CI 1.5-2.4). Amodiaquine and desethylamodiaquine caused concentration-dependent decreases in pulse rate (1.9 beats/min per 100 nmol/L; 95% CI 1.5-2.4) and blood pressure, and prolonged the QT interval.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: